Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Cancer Science|July 15, 2020
Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patientsKeiichi Hatakeyama, Takeshi Nagashima, Keiichi Ohshima, et al.
Scientific Reports|March 17, 2023
Characterization of pancreatic cancer with ultra-low tumor mutational burdenTaisuke Imamura, Ryo Ashida, Keiichi Ohshima, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|November 29, 2023
Risk factors for lateral lymph node metastasis based on the molecular profiling of rectal cancerShunsuke Kasai, Hitoshi Hino, Keiichi Hatakeyama, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 10, 2023
Molecular profile of poorly cohesive gastric carcinoma with special reference to survivalYusuke Koseki, Keiichi Hatakeyama, Masanori Terashima, et al.
Liver Cancer|October 9, 2025
Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-UpYuya Miura, Yukiyasu Okamura, Keiichi Ohshima, et al.
Biomedical Research (Tokyo, Japan)|October 1, 2023
Impact of somatic mutations and transcriptomic alterations on cancer aneuploidyKeiichi Hatakeyama, Takeshi Nagashima, Keiichi Ohshima, et al.
Human Genome Variation|September 30, 2021
JCGA: the Japanese version of the Cancer Genome Atlas and its contribution to the interpretation of gene alterations detected in clinical cancer genome sequencingMasakuni Serizawa, Maki Mizuguchi, Kenichi Urakami, et al.
BMC Cancer|February 20, 2021
Mutational concordance analysis provides supportive information for double cancer diagnosisKeiichi Hatakeyama, Takeshi Nagashima, Akifumi Notsu, et al.
Scientific Reports|November 21, 2025
Novel CYP2A7/CYP2A6 germline hybrids associated with mutation burden in lung cancer revealed by whole-genome long-read sequencingSumiko Ohnami, Keiichi Hatakeyama, Takeshi Nagashima, et al.
Surgery Today|July 31, 2024
The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasisKai Chen, Yukiyasu Okamura, Keiichi Hatakeyama, et al.
Pageof 7